Henning RJ. Type-2 diabetes mellitus and cardiovascular disease. Future Cardiol Engl. 2018;14:491–509.

Article  CAS  Google Scholar 

Avdic T, Carlsen HK, Rawshani A, Gudbjörnsdottir S, Mandalenakis Z, Eliasson B. Risk factors for and risk of all-cause and atherosclerotic cardiovascular disease mortality in people with type 2 diabetes and peripheral artery disease: an observational, register-based cohort study. Cardiovasc Diabetol. BioMed Central Ltd; 2024;23:1–11. Available from: https://cardiab.biomedcentral.com/articles/10.1186/s12933-024-02226-x.  [Cited 5 Feb 2025].

Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I., Eur Heart J, Oxford A. 2013;34:2436–43. Available from: https://doi.org/10.1093/eurheartj/eht149. [Cited 5 Feb 2025].

Sugimoto S, Mena HA, Sansbury BE, Kobayashi S, Tsuji T, Wang C-H, et al. Brown adipose tissue-derived MaR2 contributes to cold-induced resolution of inflammation. Nat Metab Ger. 2022;4:775–90.

Article  CAS  Google Scholar 

Hussain A. Chronic hyperglycemia and cardiovascular dysfunction: an in-depth exploration of metabolic and cellular pathways in type 2 diabetes mellitus. Cardiovasc Diabetol Endocrinol Rep Engl. 2025;11:39.

Article  Google Scholar 

Pal R, Bhadada SK. AGEs accumulation with vascular complications, glycemic control and metabolic syndrome: A narrative review. Bone United States. 2023;176:116884.

CAS  Google Scholar 

GonzálezP, Lozano P, Ros G, Solano F. Hyperglycemia and Oxidative Stress: An Integral, Updated and Critical Overview of Their Metabolic Interconnections. Int J Mol Sci Switz; 2023;24. https://doi.org/10.3390/ijms24119352.

Ciubotaru PG, Kundnani NR, Sharma A, Neagu MN, Ivan VS, Buzas R et al. Hypertension and diabetes as determinants of patient-reported quality of life in permanent atrial fibrillation. Diagnostics. 2025;15. Available from: https://www.mdpi.com/2075-4418/15/21/2674.

LiZ-H, Wang X-Y, Luo Q. The roles of advanced glycation end products in cardiovascular diseases: from mechanisms to therapeutic strategies. Front Cardiovasc Med. 2025;12. Available from: https://doi.org/10.3389/fcvm.2025.1637252.

Wang T, Li H, Wang C, Li X, Deng A, Jiao X. Diabetic retinopathy as a sentinel of systemic vascular dysfunction: shared molecular mechanisms with cardiovascular disease. Exp Eye Res. 2025;261:110644. Available from: https://www.sciencedirect.com/science/article/pii/S0014483525004166.

Sharma A, Zheng Y, Ezekowitz JA, Westerhout CM, Udell JA, Goodman SG, et al. Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine. Diabetes Care United States. 2022;45:204–12.

Article  CAS  Google Scholar 

Karlsson FH, Tremaroli V, Nookaew I, Bergström G, Behre CJ, Fagerberg B, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nat Engl. 2013;498:99–103.

Article  CAS  Google Scholar 

Larsen N, Vogensen FK, van den Berg FWJ, Nielsen DS, Andreasen AS, Pedersen BK, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One United States. 2010;5:e9085.

Article  Google Scholar 

Weiss GA, Hennet T. Mechanisms and consequences of intestinal dysbiosis. Cell Mol Life Sci Switz. 2017;74:2959–77.

Article  CAS  Google Scholar 

Karczewski J, Poniedziałek B, Adamski Z, Rzymski P. The effects of the microbiota on the host immune system. Autoimmun Engl. 2014;47:494–504.

Article  CAS  Google Scholar 

Bleau C, Karelis AD, St-Pierre DH, Lamontagne L. Crosstalk between intestinal microbiota, adipose tissue and skeletal muscle as an early event in systemic low-grade inflammation and the development of obesity and diabetes. Diabetes Metab Res Rev Engl. 2015;31:545–61.

Article  CAS  Google Scholar 

Mei Z, Wang F, Bhosle A, Dong D, Mehta R, Ghazi A et al. Strain-specific gut microbial signatures in type 2 diabetes identified in a cross-cohort analysis of 8,117 metagenomes. Nat Med. 2024;30:2265–76. Available from: https://doi.org/10.1038/s41591-024-03067-7.

Cunningham AL, Stephens JW, Harris DA. Gut microbiota influence in type 2 diabetes mellitus (T2DM). Gut Pathog Engl. 2021;13:50.

Article  CAS  Google Scholar 

He JH, Wang H, Qiu E, Qi Q, Wang Z. Gut Microbiota and Atherosclerosis: Integrative Multi-Omics and Mechanistic Insights. Curr Atheroscler Rep United States. 2025;28:1.

Article  Google Scholar 

ZhangY-Y, Chen S-T, Chen G, Zhou L, Zhou G-L, Yu X-Y et al. The Type III Secretion System (T3SS) of Escherichia Coli Promotes Atherosclerosis in Type 2 Diabetes Mellitus. Adv Sci (Weinheim, Baden-Wurttemberg, Ger. Germany). 2025;e2413296. https://doi.org/10.1002/advs.202413296.

Ma Q, Li Y, Li P, Wang M, Wang J, Tang Z, et al. Research progress in the relationship between type 2 diabetes mellitus and intestinal flora. Biomed Pharmacother Elsevier Masson. 2019;117:109138.

Article  CAS  Google Scholar 

Al-Busaidi A, Alabri O, Alomairi J, ElSharaawy A, Al Lawati A, Al Lawati H, et al. Gut Microbiota and Insulin Resistance: Understanding the Mechanism of Better Treatment of Type 2 Diabetes Mellitus. Curr Diabetes Rev United Arab Emirates. 2024;21:e170124225723.

Article  Google Scholar 

Utzschneider KM, Kratz M, Damman CJ, Hullar M. Mechanisms Linking the Gut Microbiome and Glucose Metabolism. J Clin Endocrinol Metab United States. 2016;101:1445–54.

Article  CAS  Google Scholar 

Jie Z, Xia H, Zhong S-L, Feng Q, Li S, Liang S, et al. The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun Engl. 2017;8:845.

Article  Google Scholar 

Zhang L, Wang Z, Zhang X, Zhao L, Chu J, Li H, et al. Alterations of the Gut Microbiota in Patients with Diabetic Nephropathy. Microbiol Spectr United States. 2022;10:e0032422.

Article  Google Scholar 

Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract Elsevier. 2022;183:109119.

Article  Google Scholar 

Beckman JA, Paneni F, Cosentino F, Creager MA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J Engl. 2013;34:2444–52.

Article  Google Scholar 

Cerf-Bensussan N, Gaboriau-Routhiau V. The immune system and the gut microbiota: friends or foes? Nat Rev Immunol Engl. 2010;10:735–44.

Article  CAS  Google Scholar 

Zheng X, Zhang Z, Shan T, Zhao M, Lu H, Zhang L, et al. Study on the Mechanism of Bifidobacterium animalis subsp. lactis F1-3-2 Regulating Bile Acid Metabolism Through TMA-TMAO Pathway to Improve Atherosclerosis. Probiotics Antimicrob Proteins United States. 2025;17:4851–66.

Article  CAS  Google Scholar 

Anto L, Blesso CN. Interplay between diet, the gut microbiome, and atherosclerosis: Role of dysbiosis and microbial metabolites on inflammation and disordered lipid metabolism. J Nutr Biochem United States. 2022;105:108991.

Article  CAS  Google Scholar 

Jiang S, Gong L, Zheng H. [Research progress on the correlation between Akkermansia muciniphila and cardiovascular diseases]. Nan Fang Yi Ke Da Xue Xue Bao China. 2026;46:473–8.

Google Scholar 

Yuan Y, Zhang J, Xu J, Xia X, Yu M, Zha L et al. Association of Decreased Fecal Microbiota Akkermansia with Increased High-Sensitivity C-Reactive Protein Levels in Patients with Unstable Angina. Curr Med Sci. 2025;45:494–505. Available from: https://doi.org/10.1007/s11596-025-00050-2.

GurungM, Li Z, You H, Rodrigues R, Jump DB, Morgun A, et al. Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine Neth. 2020;51:102590. https://doi.org/10.1016/j.ebiom.2019.11.051.

Article  Google Scholar 

Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nat Engl. 2012;490:55–60.

Article  CAS  Google Scholar 

Wang Z, Peters BA, Usyk M, Xing J, Hanna DB, Wang T et al. Gut Microbiota, Plasma Metabolomic Profiles, and Carotid Artery Atherosclerosis in HIV Infection. Arterioscler Thromb Vasc Biol. 2022;42:1081–93. Available from: https://www.ahajournals.org/doi/abs/10.1161/ATVBAHA.121.317276.

Zhu S, Xu K, Jiang Y, Zhu C, Suo C, Cui M et al. The gut microbiome in subclinical atherosclerosis: a population-based multiphenotype analysis. Rheumatology. 2022;61:258–69. Available from: https://doi.org/10.1093/rheumatology/keab309.

Chong S, Lin M, Chong D, Jensen S, Lau NS. A systematic review on gut microbiota in type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2025;15. Available from: https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1486793.

Gawałko M, Kociemba W, Sanders P, Linz D. Gut microbiome and atrial fibrillation: mechanistic insights metabolites and comorbidities. Systematic review. Gut Microbes United States. 2025;17:2570423.

Article  Google Scholar 

Wang Z, Peters BA, Bryant M, Hanna DB, Schwartz T, Wang T, et al. Gut microbiota, circulating inflammatory markers and metabolites, and carotid artery atherosclerosis in HIV infection. Microbiome Engl. 2023;11:119.

Article  CAS  Google Scholar 

Karlsson FH, Fåk F, Nookaew I, Tremaroli V, Fagerberg B, Petranovic D et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun. 2012;3:1245. Available from: https://doi.org/10.1038/ncomms2266.

Rittiphairoj T, Pongpirul K, Janchot K, Mueller NT, Li T. Probiotics Contribute to Glycemic Control in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Adv Nutr United States. 2021;12:722–34.

Google Scholar 

Mao Y, Kong C, Zang T, You L, Wang L-S, Shen L, et al. Impact of the gut microbiome on atherosclerosis. mLife Australia. 2024;3:167–75.

Article  CAS  Google Scholar 

Zhai L, Xiao H, Lin C, Wong HLX, Lam YY, Gong M et al. Gut microbiota-derived tryptamine and phenethylamine impair insulin sensitivity in metabolic syndrome and irritable bowel syndrome. Nat Commun. 2023;14:4986. Available from: https://doi.org/10.1038/s41467-023-40552-y.

Sayols-Baixeras S, Dekkers KF, Baldanzi G, Jönsson D, Hammar U, Lin Y-T et al. Streptococcus Species Abundance in the Gut Is Linked to Subclinical Coronary Atherosclerosis in 8973 Participants From the SCAPIS Cohort. Circulation. American Heart Association; 2023;148:459–72. Available from: https://doi.org/10.1161/CIRCULATIONAHA.123.063914.

Kampoo K, Teanpaisan R, Ledder RG, McBain AJ. Oral bacterial communities in individuals with type 2 diabetes who live in southern Thailand. Appl Environ Microbiol United States. 2014;80:662–71.

Article  CAS  Google Scholar 

Dash NR, Al Bataineh MT, Alili R, Al Safar H, Alkhayyal N, Prifti E et al. Functional alterations and predictive capacity of gut microbiome in type 2 diabetes. Sci Rep. 2023;13:22386. Available from: https://doi.org/10.1038/s41598-023-49679-w

Chen J, Qin Q, Yan S, Yang Y, Yan H, Li T, et al. Gut Microbiome Alterations in Patients With Carotid Atherosclerosis. Front Cardiovasc Med Switz. 2021;8:739093.

Article  CAS  Google Scholar 

Al-Otaibi FE, Al-Mohizea MM. Non-vertebral Veillonella species septicemia and osteomyelitis in a patient with diabetes: a case report and review of the literature. J Med Case Rep Engl. 2014;8:365.

Article  Google Scholar 

Murugesan S, Yousif G, Djekidel MN, Gentilcore G, Grivel JC, Al Khodor S. Microbial and proteomic signatures of type 2 diabetes in an Arab population. J Transl Med Engl. 2024;22:1132.

Article  CAS  Google Scholar